IN VITRO ANTIDIABETIC EFFECTS OF FERULA ASSA-FOETIDA EXTRACTS THROUGH DIPEPTIDYL PEPTIDASE IV AND α-GLUCOSIDASE INHIBITORY ACTIVITY

  • Adel Yarizade Department of Plant Biotechnology, Faculty of Agriculture, University of Guilan, Rasht, Iran.
  • HASAN HASANI KUMLEH Department of Plant Biotechnology, Faculty of Agriculture, University of Guilan, Rasht, Iran.
  • Ali Niazi nstitute of Biotechnology, Shiraz University, Shiraz, Iran

Abstract

Objective: Diabetes mellitus (DM) causes hyperglycemia, which is one of the most common diseases in the world. One of the strategies for the treatment of diabetes is maintaining postprandial glucose level through inhibition of dipeptidyl peptidase IV (DPP-IV) and α-glucosidase enzymes. The aim of this study was to determine in vitro antidiabetic potential of Ferula assa-foetida via DPP-IV and α-glucosidase inhibitory activities.

Methods: F. assa-foetida seeds were extracted in methanol, ethanol, ethanol-methanol, and water. Inhibitory activity on DPP-IV and α-glucosidase wasperformed in vitro and measured spectrophotometrically at λ=405 nm.

Results: The result showed that the F. assa-foetida seed extract is effective against both enzymes. All fractions had DPP-IV inhibitory activity, but the ethanolic fraction had the highest inhibitory activity on DPP-IV enzyme and significantly decreased DPP-IV activity (24.5%). With respect to α-glucosidase inhibitory activity, the aqueous extract has the highest inhibitory activity (28%).

Conclusion: According to the results of this study, F. assa-foetida contains DPP-IV and α-glucosidase inhibitors and could be a potential source for the discovery of active constituents as α-glucosidase and DPP-IV inhibitors to treat Type 2 DM.

 

Keywords: Diabetes mellitus, Herbal medicine, Dipeptidyl peptidase IV, α-glucosidase.

References

1. Ahrén B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab2007;21(4):517-33.
2. Rosenthal MS. The Canadian Type 2 Diabetes Sourcebook. Canada: John Wiley & Sons Canada, Ltd.; 2009. p. 34.
3. International Diabetes Federation. IDF Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015. Available from: http://www.diabetesatlas.org.
4. Brunetti L, Kalabalik J. Management of Type-2 diabetes mellitus in adults: Focus on individualizing non-insulin therapies. P T
2012;37(12):687-96.
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in Type 2 diabetes: A patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
6. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, et al. Weight management through lifestyle modification for the prevention and management of Type 2 diabetes: Rationale and strategies a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004;27:2067-73.
7. Barnett A. DPP-4 inhibitors and their potential role in the management of Type 2 diabetes. Int J Clin Pract 2006;60(11):1454-70.
8. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for Type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;CD006739.
9. Tiwari P. Recent trends in therapeutic approaches for diabetes management: A comprehensive update. J Diabetes Res 2015;2015:340838.
10. van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of Type 2 diabetes. Vasc Health Risk Manag 2008;4(6):1189-95.
11. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with Type 2 diabetes: Results from a Cochrane systematic review and meta- analysis. Diabetes Care 2005;28(1):154-63.
12. Iranshahy M, Iranshahi M. Traditional uses, phytochemistry and pharmacology of asafoetida (Ferula assa-foetida oleo-gum-resin): A review. J Ethnopharmacol 2011;134(1):1-10.
13. Dehpour AA, Ebrahimzadeh MA, Fazel NS, Mohammad NS. Antioxidant activity of the methanol extract of Ferula assa-foetida and its essential oil composition. Grasas Aceites 2009;60:405-12.
14. Lee CL, Chiang LC, Cheng LH, Liaw CC, Abd El-Razek MH, Chang FR, et al. Influenza A (H1N1) antiviral and cytotoxic agents from Ferula assa-foetida. J Nat Prod 2009;72:1568-72.
15. Patil SD, Shinde S, Kandpile P, Jain AS. Evaluation of antimicrobial activity of asafoetida. Int J Pharm Sci Res 2015;6:722-7.
16. Fatehi M, Farifteh F, Fatehi-Hassanabad Z. Antispasmodic and hypotensive effects of Ferula assa-foetida gum extract. J Ethnopharmacol 2004;91(2-3):321-4.
17. Yusufoglu HS, Soliman GA, Abdel-Rahman RF, Abdel-Kader MS, Ganaie MA, Bedir E, et al. Antihyperglycemic and antihyperlipidemic effects of Ferula assa-foetida and Ferula tenuissima extracts in diabetic rats. Pak J Biol Sci 2015;18:314-23.
18. Ooi KL, Muhammad TS, Tan ML, Sulaiman SF. Cytotoxic, apoptotic and anti-α-glucosidase activities of 3, 4-di-O-caffeoyl quinic acid, an antioxidant isolated from the polyphenolic-rich extract of Elephantopus mollis Kunth. J Ethnopharmacol 2011;135(3):685-95.
19. Matheeussen V, Lambeir AM, Jungraithmayr W, Gomez N, Mc Entee K, van der Veken P, et al. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta 2012;413(3-4):456-62.
20. Iranshahi M, Alizadeh M. Antihyperglycemic effect of asafoetida (Ferula assa-foetida Oleo-Gum-Resin) in streptozotocin-induced diabetic rats. World Appl Sci J 2012;17:157-62.
21. Azari M, Mohiti-ardekani J, Abedini S, Mozayan MR. Effect of Ferula assa-foetida on cytoplasmic membrane glucose transporter isotype-4 of C2C12 cell line. Int J Med Lab 2014;1:46-53.
22. Hasimun P, Adnyana IK, Valentina R, Lisnasari E. Potential alpha- glucosidase inhibitor from selected Zingiberaceae family. Asian J Pharm Clin Res 2016;9:164-7.
23. Pant G, Sai K, Babasaheb S, Reddy R, Sibi G. In vitro α-amylase and α-glucosidase inhibitor activities of Abutilon indicum leaves. Asian J Pharm Clin Res 2013;6:22-4.
24. Lee MK, Kim MJ, Cho SY, Park SA, Park KK, Jung UJ, et al. Hypoglycemic effect of Du-zhong (Eucommia ulmoides Oliv.) leaves in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 2005;67:22-8.
25. Sharma BR, Rhyu DY. Anti-diabetic effects of Caulerpa lentillifera: Stimulation of insulin secretion in pancreatic β-cells and enhancement of glucose uptake in adipocytes. Asian Pac J Trop Biomed 2014;4:575-80.
26. Yogisha S, Raveesha KA. Dipeptidyl peptidase IV inhibitory activity of Mangifera indica. J Nat Prod 2010;3:76-9.
27. Davis JA, Sharma S, Mittra S, Sujatha S, Kanaujia A, Shukla G, et al. Antihyperglycemic effect of Annona squamosa hexane extract in Type 2 diabetes animal model: PTP1B inhibition, a possible mechanism of action. Indian J Pharmacol 2012;44:326-32.
28. Purnomo Y, Soeatmadji DW, Sumitro SB, Widodo MA. Anti-diabetic potential of Urena lobata leaf extract through inhibition of dipeptidyl peptidase IV activity. Asian Pac J Trop Biomed 2015;5:645-9.
29. Lendeckel U, Arndt M, Wolke C, Reinhold D, Kähne T, Ansorge S. Inhibition of human leukocyte function, alanyl aminopeptidase (APN, CD13) and dipeptidylpeptidase IV (DP IV, CD26) enzymatic activities by aqueous extracts of Cistus incanus L. ssp. incanus. J Ethnopharmacol 2002;79:221-7.
30. Srivastava S, Koley TK, Singh SK, Tripathi YB. The tuber extract of Pueraria tuberosa Linn. Competitively inhibits DPP-IV activity in normoglycemic rats. Int J Pharm Pharm Sci 2015;15:227-31.
31. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 2015;38 Suppl 1:8-16.
Statistics
386 Views | 373 Downloads
Citatons
How to Cite
Yarizade, A., HASAN HASANI KUMLEH, and A. Niazi. “IN VITRO ANTIDIABETIC EFFECTS OF FERULA ASSA-FOETIDA EXTRACTS THROUGH DIPEPTIDYL PEPTIDASE IV AND α-GLUCOSIDASE INHIBITORY ACTIVITY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 5, May 2017, pp. 357-60, doi:10.22159/ajpcr.2017.v10i5.16648.
Section
Original Article(s)